Tag: BCMA
Belantamab Mafodotin to be Withdrawn from US-market
GSK has initiated the process for withdrawal of belantamab mafodotin-blmf (Blenrep®) from the US market. The withdrawal of the US marketing authorization follows the request of the US Food and Drug Administration (FDA).
European Commission Grants Conditional Marketing Authorization to GSK for the Use...
The European Commission has granted conditional marketing authorization* for the use of GlaxoSmithKline's anti-B-cell maturation antigen (BCMA) therapy belantamab mafodotin (Blenrep®) as monotherapy for...
Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab...
The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...
ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin
Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into new therapies is needed as...
GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Myeloma...
The investigational BCMA antibody-drug conjugate GSK2857916, also known as J6M0-mcMMAF, recently awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and...
